Skip to main content

CASE REPORT article

Front. Med.
Sec. Pathology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1494952

Mucin-producing urothelial-type adenocarcinoma of the prostate with a gene mutation characteristic of intestinal adenocarcinoma: case report and literature review

Provisionally accepted
Ao Yu Ao Yu 1,2*Hongbo Su Hongbo Su 3*Peiling Yu Peiling Yu 3*Siqi Cai Siqi Cai 3*Shuaixian Mu Shuaixian Mu 4*Jinhui Yu Jinhui Yu 4*Qianting Lu Qianting Lu 4*Yuan Miao Yuan Miao 3*Ailin Li Ailin Li 1*
  • 1 Liaoning Cancer Hospital, China Medical University, Shenyang, China
  • 2 Graduate School, China Medical University, Shenyang, Liaoning Province, China
  • 3 Department of Pathology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China
  • 4 Department of Gastrointestinal Cancer, Liaoning Cancer Hospital, Shenyang, Liaoning Province, China

The final, formatted version of the article will be published soon.

    We report an elderly male with mucin-producing urothelial-type adenocarcinoma of the prostate (MPUAP) and oligometastatic lung involvement, initially diagnosed as benign prostatic hyperplasia and treated with transurethral plasma resection of the prostate (TURP). Postoperative pathology indicated mucinous adenocarcinoma, with immunohistochemistry positive for CK7, CK20, and CDX-2. Next-generation sequencing (NGS) identified genetic alterations similar to those found in intestinal adenocarcinoma. After ruling out gastrointestinal and bladder tumors, MPUAP was confirmed. Ablation therapy was performed for the lung metastasis, followed by radical prostate chemoradiotherapy. Post chemoradiotherapy, the patient received XELOX + Bevacizumab regmien but switched to capecitabine monotherapy due to adverse effects. At a 12-month follow-up post-radiotherapy, no prostate recurrence was observed, though previous lung nodule ablation suggested recurrence. By reviewing historical cases, we discussed the role and significance of radical resection and TURP in MPUAP. NGS is recommended for patients with MPUAP, and regarding chemotherapy, treatment options for colorectal cancer are worth considering.

    Keywords: Mucin-producing adenocarcinoma, Urothelial-type adenocarcinoma, Prostate, Gene sequencing, Radiotherapy

    Received: 11 Sep 2024; Accepted: 31 Dec 2024.

    Copyright: © 2024 Yu, Su, Yu, Cai, Mu, Yu, Lu, Miao and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Ao Yu, Liaoning Cancer Hospital, China Medical University, Shenyang, China
    Hongbo Su, Department of Pathology, First Affiliated Hospital of China Medical University, Shenyang, 110001, Liaoning Province, China
    Peiling Yu, Department of Pathology, First Affiliated Hospital of China Medical University, Shenyang, 110001, Liaoning Province, China
    Siqi Cai, Department of Pathology, First Affiliated Hospital of China Medical University, Shenyang, 110001, Liaoning Province, China
    Shuaixian Mu, Department of Gastrointestinal Cancer, Liaoning Cancer Hospital, Shenyang, Liaoning Province, China
    Jinhui Yu, Department of Gastrointestinal Cancer, Liaoning Cancer Hospital, Shenyang, Liaoning Province, China
    Qianting Lu, Department of Gastrointestinal Cancer, Liaoning Cancer Hospital, Shenyang, Liaoning Province, China
    Yuan Miao, Department of Pathology, First Affiliated Hospital of China Medical University, Shenyang, 110001, Liaoning Province, China
    Ailin Li, Liaoning Cancer Hospital, China Medical University, Shenyang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.